期刊文献+

静脉注射利喜定(乌拉地尔)治疗老年充血性心力衰竭的临床观察 被引量:5

下载PDF
导出
摘要 目的观察利喜定(乌拉地尔)治疗充血性心力衰竭(CHF)的疗效。方法选择CHF患者30例,给予利喜定静脉注射,用药前后测定患者心率(HR)、血压(BP)、平均肺动脉压(MPAP)、肺毛细血管楔压(PCWP)、心排血量(CO)、体循环阻力(SVR)、肺循环阻力(PVR)、及心排指数(CI),并观察CHF临床症状的变化。结果30例患者中,有26例用药后出现MPAP、PCWP、SVR、PVR降低(P<0.01),CI增加(P<0.05),HR、BP无明显变化,CHF的临床症状改善,4例患者无效,总有效率为86.7%。无反射性心动过速等不良反应出现,副作用小。结论利喜定能有效地改善CHF患者血流动力学与临床症状,不良反应小,疗效确切,是治疗CHF的一种理想药物。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2007年第11期1078-1079,共2页 Chinese Journal of Gerontology
基金 山东省科学技术发展重点项目(2002BB1CJA1)
  • 相关文献

参考文献9

  • 1Kaplan HR,Smith RD.Antihypertensive drugs:proposed sites and mechanisms of action[J].Fed Proc,1981;40(8):2268-74.
  • 2Forster C.Interaction of 5-methyl-urapidil with alpha 1-adrenoceptors in canine blood vessels:impact of pacing-induced heart failure[J].Eur J Pharmacol,1996; 318(1):55-63.
  • 3贾晓鹏,申莲玉,邹国鼎.盐酸乌拉地尔与多巴酚丁胺联用治疗重症急性充血性心力衰竭的临床观察[J].中国药房,2004,15(7):423-424. 被引量:3
  • 4陈桂玲,董莉,等.利喜定治疗充血性心力衰竭的疗效观察[J].中国药房,2001,12(8):486-487. 被引量:15
  • 5Stangl K,Dschietzig T,Richter C,et al.Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure:acute effects of vasodilator therapy[J].Circulation,2000;102(10):1132-8.
  • 6戴闺柱.心力衰竭诊断与治疗研究进展[J].中华心血管病杂志,2003,31(9):641-645. 被引量:306
  • 7Kirsten R,Nelson K,Kirsten D,et al.Clinical pharmacokinetics of vasodilators[J].Clin Pharmacokinet,1998;35(1):9-36.
  • 8Drobinski G,Montalescot G,Fossier JM,et al.Effects of urapidil by intravenous injection on pulmonary circulation and cardiac function in left ventricular failure[J].Ann Cardiol Angeiol,1993;42(3):167-72.
  • 9Balla E,Fenoglio L,Ravera E,et al.Urapidil and dopamine in severe heart failure.A clinical case[J].Minerva Anestesiol,1992;58(11):1253-5.

二级参考文献6

共引文献317

同被引文献41

  • 1中国高血压防治指南(3)[J].中国卒中杂志,2006,1(10):724-731. 被引量:6
  • 2Holzer-Richling N,Holzer M,Herkner H,et al.Randomized place-bo controlled trial of furosemide on subjective perception of dyspnoeain patients with pulmonary oedema because of hypertensive crisis[J].Eur J Clin Invest,2011;41(6):627-34.
  • 3Tulman DB,Stawicki SP,Papadimos TJ,et al.Advances in man-agement of acute hypertension:a concise review[J].Discov Med,2012;13(72):375-383.
  • 4Marik PE,Rivera R.Hypertensive emergencies:an update[J].CurrOpin Crit Care,2011;17(6):569-580.
  • 5Chester M,Seedorf G,Tourneux P,et al. Cinaciguat, a soluble guany- late cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension [ J ]. Am J Physiol Lung Cell Mol Physio1,2011,301 ( 5 ) : 755-764.
  • 6Modolo NS, Modolo MP, Marton MA, et al. Intravenous versus inhala- tion anaesthesia for one-lung ventilation [ J ]. Cochrane Database Syst Rev,2013,7:6313.
  • 7AME. Hypoxic pulmonary vasoconstriction[ J ]. Essays Biochem,2007, 43:61-76.
  • 8Adnot S,Samoyeau R, Weitzenblum E. Treatment of pulmonary hyper- tension in patients with chronic obstructive pulmonary disease:position of vasodilators with special focus on urapidil [ J ]. Blood Press Suppl, 1995,3:47-57.
  • 9Vizza CD, Letizia C, Badagliacca R, et al. Relationship between base- line ET-1 plasma levels and outcome in patients with idiopathic pulmo- nary hypertension treated with bosentan [ J ]. Int J Cardiol, 2013,167 ( 1 ) :220-224.
  • 10Hakim TS, Pedoto A, Mangar D, et al. Nitric oxide plays a minimal role in hypoxic pulmonary vasoconstriction in isolated rat lungs[J]. Respir Physiol Neurobiol,2013,189 ( 1 ) :93-98.

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部